logo

Atara Biotherapeutics, Inc. (ATRA)



Trade ATRA now with
  Date
  Headline
1/4/2021 8:46:53 AM Atara Provides Regulatory Update For Tab-Cel For Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
12/8/2020 9:43:10 PM Atara Biotherapeutics Prices Underwritten Public Offering Of 5.10 Mln Shares At $24.50/shr
12/7/2020 7:21:53 AM Atara Biotherapeutics Presents First Preclinical Evaluation Of ATA3219 At ASH
11/15/2020 10:05:49 AM Atara Biotherapeutics To Present 15-Month Safety And Efficacy Data In Phase1a Study Of ATA188 At ECF
11/12/2020 8:36:56 AM Atara Presents Data On ATA3271, Next-Generation Allogeneic Mesothelin-Targeted CAR T To Treat Solid Tumors
9/11/2020 8:08:01 AM Atara Announces All Progressive Multiple Sclerosis Patients with Disability Improvement At Six Months
9/8/2020 7:05:46 AM Atara Biotherapeutics Announces FDA Clearance Of IND For ATA2271 For The Treatment Of Advanced Mesothelioma
9/1/2020 7:13:36 AM Atara Biotherapeutics To Present 12-Month Data From Four Cohorts In Phase 1a Study Of ATA188 At MSVirtual2020
6/17/2020 8:51:10 AM Atara : First Patient Enrolled In Study Of Allogeneic T-cell Therapy ATA188 In Progressive Forms Of MS
5/27/2020 1:20:44 AM Atara Biotherapeutics Reports Pricing Of $175.5 Mln Public Offering
5/26/2020 7:09:53 AM Atara Biotherapeutics Presents Addl Safety And Efficacy Data From Phase 1 Study Of ATA188
5/15/2020 9:44:32 AM Atara Biotherapeutics Announces Presentation Of Late-Breaking Preclinical Data On ATA2271
4/22/2020 8:56:43 PM Atara Biotherapeutics Reports Inducement Grants
4/2/2020 8:47:03 AM Atara Biotherapeutics Says Remains On Track To Initiate A Tab-cel BLA Submission For Patients With EBV+ PTLD In H2